MedTrace Logo

Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients

NCT02767557 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 147

Last updated 2023-09-22

No results posted yet for this study

Summary

This is a multicenter center, 2-arms prospective randomized phase II trial which evaluates whether tocilizumab with gemcitabine/nab-paclitaxel is more effective than gemcitabine/nab-paclitaxel.

Conditions

  • Unresectable Pancreatic Carcinoma

Interventions

DRUG

Tocilizumab

Intravenous infusion

DRUG

Gemcitabine

Intravenous infusion

DRUG

nab-Paclitaxel

Intravenous infusion,

Sponsors & Collaborators

  • Celgene

    collaborator INDUSTRY

  • Herlev Hospital

    lead OTHER

Principal Investigators

  • Inna Chen, MD · Herlev & Gentofte Hospital

  • Olav Dajani, MD PhD · Oslo University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-26
Primary Completion
2021-08-12
Completion
2023-01-01

Countries

  • Denmark
  • Norway

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02767557 on ClinicalTrials.gov